Menu

WHO Cherry-Picked Data on Pesticide, Investigation Finds

A group evaluating glyphosate’s cancer risk omitted evidence that the chemical is not carcinogenic.

Oct 22, 2017
Ashley P. Taylor

PIXABAY, SBJ04769Update (October 26): In a statement published October 24, the IARC “rejects these false claims” that it cherry-picked data on glyphosate. IARC explains that the differences between the draft document and the report center around a review paper coauthored by a Monsanto scientist: “. . . the Working Group considered that the review article did not provide adequate information for independent evaluation of the conclusions reached by the Monsanto scientist and other authors; consequently, the draft was revised, and the text in the published Monograph is the consensus opinion of the Working Group.”

IARC stands behind its conclusions.

In writing a report about the cancer risk of glyphosate, a key ingredient in Monsanto’s weed killer Roundup, the World Health Organization (WHO) edited out references to evidence that the pesticide does not cause cancer in animals, Reuters reports in a story published yesterday (October 19).

The original WHO report, issued in 2015 by the International Agency for Research on Cancer (IARC), a semiautonomous group within the WHO, concluded that glyphosate was a “Group 2a carcinogen, a substance that probably causes cancer in people,” according to Reuters. An investigation by Reuters finds that IARC redacted evidence to the contrary from their report.

“IARC members manipulated and distorted scientific data” in the glyphosate report, Scott Partridge, Monsanto’s vice president of global strategy, tells Reuters.

See “E.U. Delays Vote On Roundup

The original report, as published, contradicts other analyses from groups around the world, according to Reuters. A subsequent analysis by a United Nations and WHO panel concluded that glyphosate from food was “unlikely” to pose a cancer risk to humans, for instance. The US Environmental Protection Agency and the European Food Safety Authority and the European Chemicals Agency have called glyphosate safe.

The conclusions of that 2015 report have had political consequences. Since its publication, Monsanto has faced litigation in the U.S. from people claiming that the pesticide caused their cancer. In the European Union (E.U.), a pending vote will determine whether to renew glyphosate’s license for sale in EU member states. If the vote is negative, glyphosate will be banned in the E.U. as of January 1, according to Reuters.

Reuters’s investigation suggests that those conclusions might have been different had the report been edited differently. “Reuters found 10 significant changes that were made between the draft chapter on animal studies and the published version of IARC’s glyphosate assessment,” according to the news report. “In each case, a negative conclusion about glyphosate leading to tumors was either deleted or replaced with a neutral or positive one. Reuters was unable to determine who made the changes.”

In two cases, for example, the report included a new statistical analysis that flipped the conclusion of a study from there being no significant link between glyphosate and cancer in mice to an association that was statistically significant, according to Reuters.

The IARC did not answer Reuters’s questions about changes to the report.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.